Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Systemic Administration

Tumor control by intravenous administration of STING ligand requires combination with precisely timed radiation therapy
Jason Baird, David Friedman, Benjamin Cottam, Marka Crittenden, Michael Gough

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P349; DOI: 10.1186/2051-1426-3-S2-P349
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
DV Smirnov, G Zhao, JM Beaurline, KE Johnson, JT Capecchi, LI Harrison, MA Tomai, JM Elvecrog, DM Klinman, JP Vasilakos

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P138; DOI: 10.1186/2051-1426-1-S1-P138